1. Signaling Pathways
  2. Apoptosis
  3. TNF Receptor

TNF Receptor (肿瘤坏死因子)

Tumor Necrosis Factor Receptor; TNFR

肿瘤坏死因子 (TNF) 是细胞凋亡以及炎症和免疫的主要介质,并且与多种人类疾病的发病机制有关,包括败血症、糖尿病、癌症、骨质疏松症、多发性硬化症、类风湿性关节炎和炎症性肠病。

TNF-α 是一种 17 kDa 蛋白质,由 157 个氨基酸组成,在溶液中为同源三聚体。在人类中,该基因位于 6 号染色体上。其生物活性主要受可溶性 TNF-α 结合受体的调节。TNF-α 主要由活化的巨噬细胞、T 淋巴细胞和自然杀伤细胞产生。已知多种其他细胞的表达较低,包括成纤维细胞、平滑肌细胞和肿瘤细胞。在细胞中,TNF-α 合成为 pro-TNF (26 kDa),它与膜结合,在 TNF 转换酶 (TACE) 裂解其 pro 结构域后释放。

许多 TNF 诱导的细胞反应是由两种 TNF 受体 TNF-R1 和 TNF-R2 中的任一种介导的,这两种受体都属于 TNF 受体超家族。在 TNF 治疗后,转录因子 NF-κB 和 MAP 激酶(包括 ERK、p38 和 JNK)在大多数类型的细胞中被激活,在某些情况下,也可能诱导细胞凋亡或坏死。然而,诱导细胞凋亡或坏死主要是通过 TNFR1 实现的,TNFR1 也称为死亡受体。NF-κB 和 MAPK 的激活在多种细胞因子和免疫调节蛋白的诱导中起着重要作用,并且对许多炎症反应至关重要。

Tumor necrosis factor (TNF) is a major mediator of apoptosis as well as inflammation and immunity, and it has been implicated in the pathogenesis of a wide spectrum of human diseases, including sepsis, diabetes, cancer, osteoporosis, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel diseases.

TNF-α is a 17-kDa protein consisting of 157 amino acids that is a homotrimer in solution. In humans, the gene is mapped to chromosome 6. Its bioactivity is mainly regulated by soluble TNF-α–binding receptors. TNF-α is mainly produced by activated macrophages, T lymphocytes, and natural killer cells. Lower expression is known for a variety of other cells, including fibroblasts, smooth muscle cells, and tumor cells. In cells, TNF-α is synthesized as pro-TNF (26 kDa), which is membrane-bound and is released upon cleavage of its pro domain by TNF-converting enzyme (TACE).

Many of the TNF-induced cellular responses are mediated by either one of the two TNF receptors, TNF-R1 and TNF-R2, both of which belong to the TNF receptor super-family. In response to TNF treatment, the transcription factor NF-κB and MAP kinases, including ERK, p38 and JNK, are activated in most types of cells and, in some cases, apoptosis or necrosis could also be induced. However, induction of apoptosis or necrosis is mainly achieved through TNFR1, which is also known as a death receptor. Activation of the NF-κB and MAPKs plays an important role in the induction of many cytokines and immune-regulatory proteins and is pivotal for many inflammatory responses.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P990757
    Ragistomig
    Ragistomig 是一种抗 TNFRSF9/CD274IgG1 单克隆抗体,由 κ 轻链和带 λ 轻链和 IgG1 重链的可变区组成,整体结构是一个由两个相同的 IgG1 重链组成的二聚体。
    Ragistomig
  • HY-P99470
    Benufutamab

    贝奴妥单抗

    Agonist 98.62%
    Benufutamab (GEN1029) 是一种死亡受体 5 (DR5) 特异性激动性抗体。Benufutamab 是 2 种非竞争性 DR5 特异性 IgG1 抗体的混合物,每种抗体的 Fc 结构域都有一个 E430G 突变。Benufutamab 具有抗肿瘤作用。
    Benufutamab
  • HY-107909
    Theophylline sodium glycinate

    茶碱甘氨酸钠

    Inhibitor
    Theophylline (1,3-Dimethylxanthine) sodium glycinate 是有效的磷酸二酯酶 (PDE) 抑制剂,腺苷受体拮抗剂,和组蛋白脱乙酰酶 (HDAC) 活化剂。Theophylline sodium glycinate 抑制 PDE3 活性,放松气道平滑肌。Theophylline sodium glycinate 通过增加 IL-10 和抑制 NF-κ B进入细胞核而具有抗炎活性。Theophyllin sodium glycinate 诱发细胞凋亡 (apoptosis)。Theophylline sodium glycinate 可用于哮喘和慢性阻塞性肺疾病 (COPD) 的研究。
    Theophylline sodium glycinate
  • HY-P990994
    Emunkitug Inhibitor
    Emunkitug 是一种靶向 TNFRSF1B 的 IgG1κ 型人源化抗体,对应的同型对照为:Human IgG1 kappa, Isotype Control (HY-P99001)。
    Emunkitug
  • HY-P990980
    Cizutamig Inhibitor
    Cizutamig 是一种靶向 TNFRSF17 的 [L-κ-H-γ1_[VH-G1(CH1-h)]_Lκ] dimer 型人源化抗体。
    Cizutamig
  • HY-P991024
    Solabafusp alfa Inhibitor
    Solabafusp alfa 是一种靶向 CD274/TNFRSF9 的 IgG4κ 型人源化抗体,对应的同型对照为:Human IgG4 (S228P) kappa, Isotype Control (HY-P99003)。
    Solabafusp alfa
  • HY-P990939
    Podentamig Inhibitor
    Podentamig 是一种靶向 CD3E/TNFRSF17 的 VH-VH'-(scFv-heavy -λ) 型嵌合抗体。
    Podentamig
  • HY-P99782
    Opinercept Inhibitor
    Opinercept 是一种重组融合蛋白,包含与人 IgG1 Fc 融合的 TNFRSF1B。Opinercept 是一种肿瘤坏死因子-alpha (TNF-alpha) 的抑制剂。Opinercept 可用于类风湿性关节炎 (RA) 的研究。
    Opinercept
  • HY-P990971
    Atenastobart Inhibitor
    Atenastobart 是一种靶向 TNFRSF9 的 IgG1λ2 型人源抗体,对应的同型对照为:Human IgG1 lambda2, Isotype Control (HY-P990096)。
    Atenastobart
  • HY-P991012
    Nuvustotug Inhibitor
    Nuvustotug 是一种靶向 TNFRSF4 的 IgG1κ 型人源抗体,对应的同型对照为:Human IgG1 kappa, Isotype Control (HY-P99001)。
    Nuvustotug
  • HY-P991003
    Ingitamig Inhibitor
    Ingitamig 是一种靶向 TNFRSF17/KLRK1 的 (G1_L-κ)_(G1-scFvkh_L-κ) 型双特异性抗体。
    Ingitamig
  • HY-B0809A
    Theophylline monohydrate

    茶碱水合物

    Inhibitor
    Theophylline (1,3-Dimethylxanthine) monohydrate 是有效的磷酸二酯酶 (PDE) 抑制剂,腺苷受体拮抗剂,和组蛋白脱乙酰酶 (HDAC) 活化剂。Theophylline (1,3-Dimethylxanthine) monohydrate 抑制 PDE3 活性,放松气道平滑肌。Theophylline (1,3-Dimethylxanthine) monohydrate 通过增加 IL-10 和抑制 NF-κ B进入细胞核而具有抗炎活性。Theophylline (1,3-Dimethylxanthine) monohydrate 诱发细胞凋亡 (apoptosis)。Theophylline (1,3-Dimethylxanthine) monohydrate 可用于哮喘和慢性阻塞性肺疾病 (COPD) 的研究。
    Theophylline monohydrate
  • HY-P99704
    Licaminlimab

    利卡明利单抗

    Inhibitor
    Licaminlimab (OCS-02) 是一种单链抗 TNF alpha 抗体片段。TNF alpha 是巨噬细胞和单核细胞在炎症过程中产生的炎症细胞因子。
    Licaminlimab
  • HY-P99499
    Cetrelimab

    西利单抗

    Activator ≥99.0%
    Cetrelimab (JNJ 63723283; JNJ 3283) 是一种靶向 PD-1 的人源 IgG4κ 单克隆抗体。Cetrelimab 结合 PD-1 的 Kd 为 1.72 nM (HEK293 细胞)。由此,Cetrelimab 阻断 PD-1PD-L1PD-L2 的相互作用 (IC50 分别为 111.7 ng/mL 和 138.6 ng/mL)。Cetrelimab 还刺激外周 T 细胞,增加细胞因子 (IFN-γ, IL-2, TNF-α) 水平,并抑制体内肿瘤生长。
    Cetrelimab
  • HY-111326
    Naphazoline

    萘甲唑啉

    Inhibitor 99.74%
    Naphazoline (Naphthazoline) 是一种有效的 α- 肾上腺素能受体 (α-adrenergic receptor) 激动剂。Naphazoline 能降低血管通透性和促进血管收缩。Naphazoline 可降低炎症因子 (TNF-α、IL-1β 和 IL-6)、细胞因子 (IFN-γIL-4)、IgE、GMCSF 和 NGF 的水平。Naphazoline 可用于非细菌性结膜炎的研究。
    Naphazoline
  • HY-168130
    TNF-α/IL-1β-IN-1 Inhibitor
    TNF-α/IL-1β-IN-1 (compund 11a) 是一种抗炎剂,能够减少 TNF-α 和 IL-1β 的表达,抑制氧化应激和心肌细胞凋亡,对脓毒性心肌损伤具备良好活性,并在体内改善心肌血流供应。
    TNF-α/IL-1β-IN-1
  • HY-N2464R
    Maltotetraose (Standard)

    麦芽四糖 (Standard)

    Maltotetraose (Standard)是 Maltotetraose 的分析标准品。本产品用于研究及分析应用。Maltotetraose 可以作为生物流体中酶联测定淀粉酶活性的一个底物。
    Maltotetraose (Standard)
  • HY-144368
    CO delivery molecule 1 Inhibitor
    CO delivery molecule 1 (compound 4) 定位于内质网、线粒体和溶酶体。CO delivery molecule 1 的亚细胞定位导致共诱导毒性效应。通过 TNF-α 抑制测定,CO delivery molecule 1 的抗炎作用在没有共释放的情况下发生在纳摩尔水平,并且随着可见光诱导的共释放而增强。
    CO delivery molecule 1
  • HY-146547
    Anti-inflammatory agent 17 Inhibitor
    Anti-inflammatory agent 17 是一种有效的具有口服活性的消炎药。Anti-inflammatory agent 17 在体外实验中抑制 IL-6 和 TNF-α 的释放且无细胞毒性。Anti-inflammatory agent 17 在体内显示出抗炎活性。Anti-inflammatory agent 17 具有研究急性肺损伤 (ALI) 的潜力。
    Anti-inflammatory agent 17
  • HY-111326S
    Naphazoline-d4 hydrochloride
    Naphazoline-d4 (hydrochloride) 是 Naphazoline hydrochloride 的氘代物。
    Naphazoline-d<sub>4</sub> hydrochloride
目录号 产品名 / 同用名 种属 表达系统
目录号 产品名 / 同用名 应用 反应物种

Following the binding of TNF to TNF receptors, TNFR1 binds to TRADD, which recruits RIPK1, TRAF2/5 and cIAP1/2 to form TNFR1 signaling complex I; TNFR2 binds to TRAF1/2 directly to recruit cIAP1/2. Both cIAP1 and cIAP2 are E3 ubiquitin ligases that add K63 linked polyubiquitin chains to RIPK1 and other components of the signaling complex. The ubiquitin ligase activity of the cIAPs is needed to recruit the LUBAC, which adds M1 linked linear polyubiquitin chains to RIPK1. K63 polyubiquitylated RIPK1 recruits TAB2, TAB3 and TAK1, which activate signaling mediated by JNK and p38, as well as the IκB kinase complex. The IKK complex then activates NF-κB signaling, which leads to the transcription of anti-apoptotic factors-such as FLIP and Bcl-XL-that promote cell survival. 

 

The formation of TNFR1 complex IIa and complex IIb depends on non-ubiquitylated RIPK1. For the formation of complex IIa, ubiquitylated RIPK1 in complex I is deubiquitylated by CYLD. This deubiquitylated RIPK1 dissociates from the membrane-bound complex and moves into the cytosol, where it interacts with TRADD, FADD, Pro-caspase 8 and FLIPL to form complex IIa. By contrast, complex IIb is formed when the RIPK1 in complex I is not ubiquitylated owing to conditions that have resulted in the depletion of cIAPs, which normally ubiquitylate RIPK1. This non-ubiquitylated RIPK1 dissociates from complex I, moves into the cytosol, and assembles with FADD, Pro-caspase 8, FLIPL and RIPK3 (but not TRADD) to form complex IIb. For either complex IIa or complex IIb to prevent necroptosis, both RIPK1 and RIPK3 must be inactivated by the cleavage activity of the Pro-caspase 8-FLIPL heterodimer or fully activated caspase 8. The Pro-caspase 8 homodimer generates active Caspase 8, which is released from complex IIa and complex IIb. This active Caspase 8 then carries out cleavage reactions to activate downstream executioner caspases and thus induce classical apoptosis. 

 

Formation of the complex IIc (necrosome) is initiated either by RIPK1 deubiquitylation mediated by CYLD or by RIPK1 non-ubiquitylation due to depletion of cIAPs, similar to complex IIa and complex IIb formation. RIPK1 recruits numerous RIPK3 molecules. They come together to form amyloid microfilaments called necrosomes. Activated RIPK3 phosphorylates and recruits MLKL, eventually leading to the formation of a supramolecular protein complex at the plasma membrane and necroptosis [1][2].

 

Reference:
[1]. Brenner D, et al. Regulation of tumour necrosis factor signalling: live or let die.Nat Rev Immunol. 2015 Jun;15(6):362-74. 
[2]. Conrad M, et al. Regulated necrosis: disease relevance and therapeutic opportunities.Nat Rev Drug Discov. 2016 May;15(5):348-66. 
 

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.